Earnings ·
Twist Bioscience Corporation reported fiscal third quarter 2026 financial results for the period ended June 30, 2026
TWSTTwist Bioscience Corp
Twist Bioscience Corporation reported fiscal third quarter 2026 financial results for the period ended June 30, 2026. The company achieved record revenue of $118.4 million, representing a 23% increase from $96.1 million in the prior year period and marking its fourteenth consecutive quarter of sequential growth. Gross margin improved to 52.8%, up 120 basis points sequentially. Management raised full-year fiscal 2026 revenue guidance to $456–$457 million, increasing the midpoint by $12 million, while reiterating expectations for fourth-quarter adjusted EBITDA breakeven. The company operates in the synthetic biology industry, providing DNA synthesis and next-generation sequencing applications.